Alector Inc. (NASDAQ: ALEC) signs a groundbreaking $2.2 billion deal with GlaxoSmithKline (GSK) for immuno-neurology development. The collaboration is highlighted in a News Channel 10 FTD interview on The Buzz Show, sparking market excitement and a surge in Alector's stock price. Tune in for a comprehensive stock review and market analysis.